pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 29 Non-oncology: 15
Oncology: 14
Under Consideration for Negotiation 28 Non-oncology: 17
Oncology: 11
Completed Negotiations 687 With Letter of Intent: 590
Without agreement: 97
Negotiations That Were Not Pursued 103

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
To be confirmed Sandoz Canada Inc. Multiple Indications
Wyost Sandoz Canada Inc. Multiple Indications
Jubbonti Sandoz Canada Inc. Multiple indications
Epkinly (pTAP negotiation) AbbVie Corporation For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Paxlovid Pfizer Canada ULC Mild-to-moderate COVID-19, treatment
Rinvoq AbbVie Corporation Crohn's disease
Oxlumo Alnylam Netherlands B.V. primary hyperoxaluria type 1
Rinvoq AbbVie Corporation Ulcerative Colitis
Rinvoq AbbVie Corporation Ankylosing spondylitis
Vyalev AbbVie Corporation For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease.
Nucala GlaxoSmithKline Inc. Add-on maintenance treatment of severe eosinophilic asthma in children (aged 6 years and older)
Nucala GlaxoSmithKline Inc. Severe chronic rhinosinusitis with nasal polyps

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Korsuva Otsuka Canada Pharmaceutical Inc. For the treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis
Abecma Celgene Inc. For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment